03/05/2026
HUGE NEWS!!!!
*Impending FDA Peptide Reclassification!* 🎉🎉🎉
RFK Jr. quietly announced last Friday, Feb 27 that about 14 of 19 previously “restricted” peptides will return to legal compounding status, probably in the next few weeks!�
Backstory:�- In late 2023 and 2024, the FDA placed a group of 19 of the most popular and tremendously helpful peptides into “Category 2”, which is essentially a “do not compound” designation: they did this on the basis of what they called “significant safety concerns or lack adequate human data for pharmacy compounding.” Frankly, some 💩
And so fast forward to today: the legal basis for this current reclassification of peptides is that the FDA actually lacked the required evidence to justify the original ban back in 2023/2024, so now, they’re backpedaling. YAY!
The peptides affected include most of the big hitters clinicians, biohackers ans everyone in between is loving today: BPC-157, Thymosin Alpha-1, CJC-1295, Selank, Semax, KPV, MOTS-C, GHK-Cu, and others. Five peptides with weaker safety profiles may remain restricted.
* Moving from Category 2 to Category 1 allows licensed compounding pharmacies to legally prepare these peptides with a physician’s prescription.
* This does NOT mean these peptides are now “FDA-approved drugs,” It simply means that, if and when formal guidance is issued, licensed compounding pharmacies would be allowed to prepare them again for individual patients, under physician orders, within the guardrails of federal and state law. This landscape is in motion, and details may shift.
* Official FDA timeline is expected within weeks, though patients should monitor formal agency updates.